Skip to main content

Advertisement

SpringerLink
Log in

Clinical tolerance and efficacy of anti-parasitic treatment with albendazole in patients with alveolar echinococcosis: long-term follow-up observation in 117 patients

  • Treatment and Prophylaxis - Original Paper
  • Published:
Parasitology Research Aims and scope Submit manuscript

Abstract

Alveolar echinococcosis is the most severe worm disease primarily detected in the liver. This study aimed to determine the clinical tolerance and efficacy of albendazole in patients with alveolar echinococcosis, depending on the volume of previous surgical treatment or its absence and the duration of anti-parasitic therapy. We retrospectively (over the last 15 years) analyzed the data of 117 patients, who were divided into 4 groups according to curability: R0 (radical resection), R1+2 (incomplete resection), Nr (unresectable), and Rr (recurrence). All of them received albendazole from 3 months to 11 years, depending on the volume of resection. We evaluated patients’ tolerability of albendazole according to the level of hepatic transaminases and blood cell count. The effectiveness of anti-parasitic treatment was evaluated by imaging studies and the absence of serum antibodies. There was no direct relationship between the frequency of adverse reactions and the duration of taking albendazole (r − 0.20229). Adverse reactions were significantly more often observed in unresectable patients (p < 0.01), which is most likely associated with the general serious condition of the patients and with individual drug intolerance. The effectiveness of the anti-parasitic treatment was manifested in the inhibition of tumor development in 88% of patients in group R1+2 and 60% in group Nr. Follow-up of group R0 patients from 3 to 14 years did not reveal new lesions of the liver and other organs. The chance of a complete cure depends on the early detection of a parasitic tumor and can reach 50%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU (1994) Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss echinococcosis study group. Hepatology 19:735–742. https://doi.org/10.1002/hep.1840190328

    Article  CAS  PubMed  Google Scholar 

  • Andreyanov ON (2020) [Examining Echinococcus multilocularis infection in some Midland Russia predatory animal species]. (Article in Russian). Russian Journal of Infection and Immunity 10:193–196

    Article  Google Scholar 

  • Bresson-Hadni S, Blagosklonov O, Knapp J, Grenouillet F, Sako Y, Delabrousse E, Brientini MP, Richou C, Minello A, Antonino AT, Gillet M, Ito A, Mantion GA, Vuitton DA (2011) Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transpl. 17(7):855–865. https://doi.org/10.1002/lt.22299

    Article  PubMed  Google Scholar 

  • Bresson-Hadni S, Vuitton DA, Bartholomot B, Heyd B, Godart D, Meyer JP, Hrusovsky S, Becker MC, Mantion G, Lenys D, Miguet JP (2000) A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur J Gastroenterol Hepatol. 12:327e336. https://doi.org/10.1097/00042737-200012030-00011

    Article  Google Scholar 

  • Brunetti E, Kern P, Vuitton DA (2010) Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 114:1–16. https://doi.org/10.1016/j.actatropica.2009.11.001

    Article  PubMed  Google Scholar 

  • Crouzet J, Grenouillet F, Delabrousse E, Blagosklonov O, Thevenot T, Di Martino V, Piarroux R, Mantion GA, Bresson-Hadni S (2010) Personalized management of patients with inoperable alveolar echinococcosis undergoing treatment with albendazole: usefulness of positron-emission-tomography combined with serological and computed tomography follow-up. Clin Microbiol Infect. 16(6):788–791. https://doi.org/10.1111/j.1469-0691.2009.02924.x

    Article  CAS  PubMed  Google Scholar 

  • Davidson RK, Romig T, Jenkins E, Tryland M, Robertson LJ (2012) The impact of globalisation on the distribution of Echinococcus multilocularis. Trend Parasitol. 28(6):239–247. https://doi.org/10.1016/j.pt.2012.03.004

    Article  Google Scholar 

  • Davis A, Pawlowski ZS, Dixon H (1986) Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bull World Health Organ. 64:383–388

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gottstein B, Stojkovic M, Vuitton DA, Millon L, Marcinkute A, Deplazes P (2015) Threat of alveolar echinococcosis to public health - a challenge for Europe. Trends Parasitol. 31(9):407–412. https://doi.org/10.1016/j.pt.2015.06.001

    Article  PubMed  Google Scholar 

  • Grüner B, Kern P, Mayer B, Gräter T, Hillenbrand A, Barth TEF, Muche R, Henne-Bruns D, Kratzer W, Kern P (2017) Comprehensive diagnosis and treatment of alveolar echinococcosis: a single-center, long-term observational study of 312 patients in Germany. GMS Infect Dis 5:Doc01. https://doi.org/10.3205/id000027. eCollection 2017.

  • Horton J (2003) Albendazole for the treatment of echinococcosis. Fundam Clin Pharmacol. 17(2):205–212. https://doi.org/10.1046/j.1472-8206.2003.00171.x

    Article  CAS  PubMed  Google Scholar 

  • Kadry Z, Renner EC, Bachmann LM, Attigah N, Renner EL, Ammann RW, Clavien PA (2005) Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br J Surg. 92(9):1110–1116. https://doi.org/10.1002/bjs.4998

    Article  CAS  PubMed  Google Scholar 

  • Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, Vuitton DA (2017) The echinococcoses: diagnosis, clinical management and burden of disease. Adv Parasitol. 96:259–369. https://doi.org/10.1016/bs.apar.2016.09.006

    Article  CAS  PubMed  Google Scholar 

  • Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, Kratzer W, Bresson-Hadni S (2006) WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 55(suppl):283–287. https://doi.org/10.1016/j.parint.2005.11.041

    Article  Google Scholar 

  • Piarroux M, Piarroux R, Giorgi R, Knapp J, Bardonnet K, Sudre B, Watelet J, Dumortier J, Gérard A, Beytout J, Abergel A, Mantion G, Vuitton DA, Bresson-Hadni S (2011) Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients. J Hepatol. 55(5):1025–1033. https://doi.org/10.1016/j.jhep.2011.02.018

    Article  PubMed  Google Scholar 

  • Poletaeva OG, Starkova TV, Kovrova EA, Legon'kov IuA, Tumol'skaia NI, Krasovskaia NN, Stepanova EV (2011) [Use of an enzyme immunoassay test system with cystic Echinococcus antigen to diagnose echinococcosis alveolaris (multilocularis) (alveococcosis)] (Article in Russian). Med Parazitol (Mosk) (2):44-45.

  • Reuter S, Buck A, Manfras B, Seitz HM, Darge K, Reske SN, Kern P (2004) Structured treatment interruption in patients with alveolar echinococcosis. Hepatology. 39:509–517. https://doi.org/10.1002/hep.20078

    Article  PubMed  Google Scholar 

  • Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P (2000) Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother. 46:451–456. https://doi.org/10.1093/jac/46.3.451

    Article  CAS  PubMed  Google Scholar 

  • Schantz PM, Van den Bossche H, Eckert JZ (1982) Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Parasitenkd 67(1):5–26. https://doi.org/10.1007/BF00929509

    Article  CAS  Google Scholar 

  • Tappe D, Sako Y, Itoh S, Frosch M, Grüner B, Kern P, Ito A (2010) Immunoglobulin G subclass responses to recombinant Em18 in the follow-up of patients with alveolar echinococcosis in different clinical stages. Clin Vaccine Immunol. 17(6):944–948. https://doi.org/10.1128/CVI.00026-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Torgerson PR, Schweiger A, Deplazes P, Pohar M, Reichen J, Ammann RW, Tarr PE, Halkik N, Müllhaupt B (2008) Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol. 49(1):72–77

    Article  Google Scholar 

  • Tumol'skaia NI, Zavoĭkin, VD, Mazmanian MV, Sergiev VP (2013) [Alveolar echinococcosis in European Russia]. Med Parazitol (Mosk); Apr-Jun;(2):36-37. [Article in Russian]

  • Vuitton DA, Bresson-Hadni S (2014) Alveolar echinococcosis: evaluation of therapeutic strategies. Expert Opin Orphan Drugs 2(1):67–86. https://doi.org/10.1517/21678707.2014.870033

    Article  CAS  Google Scholar 

  • Vuitton DA (2009) Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus? Expert Rev Anti Infect Ther. 7:145–149. https://doi.org/10.1586/14787210.7.2.145

    Article  CAS  PubMed  Google Scholar 

  • Wen H, Vuitton L, Tuxun T, Li J, Vuitton DA, Zhang W, McManus DP (2019) Echinococcosis: advances in the 21st century. Clin Microbiol Rev 32(2):e00075-18. https://doi.org/10.1128/CMR.00075-18.Print 2019 Mar 20

  • Zavoikin VD, Zelya OP, Tumolskaya NI (2020) The importance of uninterrupted albendazole treatment in patients with unresectable alveolar echinococcosis undergoing liver transplantation. Transpl Infect Dis. 00:e13291. https://doi.org/10.1111/tid.13291

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow, Russia

    Valerij D. Zavoikin, Olga P. Zelya & Nelli I. Tumolskaya

Authors
  1. Valerij D. Zavoikin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olga P. Zelya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nelli I. Tumolskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olga P. Zelya.

Ethics declarations

Ethical approval

Ethical approval was not required for this retrospective study.

Conflict of interest

The authors declare no competing interests.

Additional information

Section Editor: Bruno Gottstein

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zavoikin, V.D., Zelya, O.P. & Tumolskaya, N.I. Clinical tolerance and efficacy of anti-parasitic treatment with albendazole in patients with alveolar echinococcosis: long-term follow-up observation in 117 patients. Parasitol Res 120, 3603–3610 (2021). https://doi.org/10.1007/s00436-021-07297-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00436-021-07297-3

Keywords

Search

Navigation